Compare Eli Lilly And Co (LLY) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Prologis Inc — how do they compare? Eli Lilly And Co trades at $1,179.71 (market cap $1.02T), while Prologis Inc trades at $149.1 (market cap $137.50B). The key difference: Eli Lilly And Co is far larger — about 7.4× Prologis Inc's market cap, and Prologis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals.
| LLY | PLD | |
|---|---|---|
Market Cap | $1.02T | $137.50B |
Sector | Health | Real Estate |
52-Week High | $1.24K | $149.96 |
52-Week Low | $625.65 | $104.08 |
Enterprise Value | $1.06T | $172.18B |
Dividend Yield | 0.6% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.
Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.
PLD trades at $149.94, up 0.15% with a bullish technical outlook. The stock shows strong fundamentals with revenue growth to $8.79B in 2025 and a net income margin of 45.79%. Recent Q2 2026 earnings beat expectations, and analyst consensus is positive with a $156.56 price target. The company is actively pursuing acquisition opportunities, as seen in recent Segro takeover attempts.
The outlook for PLD remains favorable due to consistent earnings beats and strategic expansion. Key risks include high valuation multiples and integration challenges from potential acquisitions. Institutional ownership is increasing, supporting a bullish sentiment, though investors should monitor debt levels which have risen to 37.2% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
